ENDRA Life Sciences Inc. — Director's Dealing 2020

Apr 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2020-04-09

Reporting Person: Basenese Lou (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-09	Common Stock	A	41587	$0.00	Acquired	41587	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-09	Stock Option (right to buy)	$0.70	A	50000	Acquired	2030-04-09	Common Stock (50000)	Direct

Footnotes

F1: Represents restricted stock units granted in lieu of the Reporting Person's cash retainer payable under the Issuer's Non-Employee Director Compensation Policy for the second, third and fourth quarters of 2020. The restricted stock units vest in three equal installments on the last day of each such calendar quarter. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes unvested restricted stock units.

F3: Represents a stock option award granted on April 9, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy.

F4: This stock option grant becomes exercisable in three equal annual installments beginning April 9, 2021.